ALK expands Catalent deal, adding 300 million tablets of annual capacity
AI Summary- ALK expanded its contract manufacturing partnership with Catalent for allergy tablets.
- 300 million additional tablets will lift annual capacity to 1.1 billion from the early 2030s.
- ALK will invest approximately DKK 500 million over three years to secure capacity expansion.